PA
ALLO icon

Parallel Advisors’s Allogene Therapeutics ALLO Stock Holding History

Parallel Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.49K Hold
1,198
– – ﹤0.01% 3467
2026
Q1 		$2.92K Hold
1,198
– – ﹤0.01% 3239
2025
Q4 		$1.64K Sell
1,198
-287
-19% -$379 ﹤0.01% 3188
2025
Q3 		$1.84K Buy
+1,485
New +$1.77K ﹤0.01% 3070
2025
Q2 		– Sell
-114
Closed -$166 – 3542
2025
Q1 		$166 Sell
114
-107
-48% -$202 ﹤0.01% 3406
2024
Q4 		$471 Hold
221
– – ﹤0.01% 3233
2024
Q3 		$619 Hold
221
– – ﹤0.01% 3144
2024
Q2 		$515 Buy
+221
New +$652 ﹤0.01% 3091
2024
Q1 		– Sell
-32
Closed -$103 – 3297
2023
Q4 		$103 Sell
32
-536
-94% -$1.52K ﹤0.01% 3229
2023
Q3 		$1.8K Buy
568
+230
+68% +$1.01K ﹤0.01% 2858
2023
Q2 		$1.68K Buy
338
+40
+13% +$216 ﹤0.01% 2800
2023
Q1 		$1.47K Hold
298
– – ﹤0.01% 2858
2022
Q4 		$1.87K Buy
298
+174
+140% +$1.61K ﹤0.01% 2709
2022
Q3 		$1K Sell
124
-464
-79% -$6.3K ﹤0.01% 2834
2022
Q2 		$7K Sell
588
-286
-33% -$2.54K ﹤0.01% 2115
2022
Q1 		$8K Sell
874
-402
-32% -$4.19K ﹤0.01% 2098
2021
Q4 		$19K Hold
1,276
– – ﹤0.01% 1803
2021
Q3 		$33K Sell
1,276
-389
-23% -$9.23K ﹤0.01% 1485
2021
Q2 		$43K Buy
1,665
+400
+32% +$11.4K ﹤0.01% 1316
2021
Q1 		$45K Hold
1,265
– – ﹤0.01% 1220
2020
Q4 		$32K Sell
1,265
-134
-10% -$4.37K ﹤0.01% 1277
2020
Q3 		$53K Buy
1,399
+477
+52% +$18K ﹤0.01% 1040
2020
Q2 		$39K Sell
922
-130
-12% -$4.7K ﹤0.01% 1140
2020
Q1 		$20K Buy
1,052
+800
+317% +$19.1K ﹤0.01% 1306
2019
Q4 		$7K Hold
252
– – ﹤0.01% 1840
2019
Q3 		$7K Hold
252
– – ﹤0.01% 1783
2019
Q2 		$7K Hold
252
– – ﹤0.01% 1695
2019
Q1 		$7K Buy
+252
New +$7.31K ﹤0.01% 1654

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Parallel Advisors's ALLO Position: Q2 2026 in Review

Parallel Advisors held its Allogene Therapeutics (ALLO) position steady in Q2 2026 at 1,198 shares worth $2.49K. The position accounts for ﹤0.01% of the portfolio, ranked #3467.

Parallel Advisors first reported a position in ALLO in Q1 2019 and has held it in 28 quarters since. The position peaked at $53K in Q3 2020. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Parallel Advisors held 1,198 shares of Allogene Therapeutics worth $2.49K as of Q2 2026.
  • Parallel Advisors left its Allogene Therapeutics share count unchanged in Q2 2026.
  • Allogene Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3467 holding.
  • Parallel Advisors first reported a position in Allogene Therapeutics in Q1 2019 and has held it in 28 quarters since.
  • Parallel Advisors's Allogene Therapeutics position peaked at $53K in Q3 2020.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.